ASCO Annual Meeting

Bile Duct Cancer Continues to Respond to Zanidatamab, Per Longer Follow-Up

June 3rd 2024, 9:00pm

Article

Zanidatamab continued to lead to responses and improved overall survival in pretreated HER2-positive biliary tract cancer.

Reblozyl Continues to Improve MDS Transfusion Independence

June 3rd 2024, 7:00pm

Article

Patients with myelodysplastic syndromes tended to have longer periods of time without needing a red blood cell transfusion when treated with Reblozyl.

An Expert Breakdown of SurVaxM, the Novel Brain Cancer Vaccine

June 3rd 2024, 3:00pm

Video

SurVaxM, which is being studied in gliobastoma, targets a certain protein that is found on the brain cancer cells.

Safety Profile of Lower-Dose Oral Onureg Remains Consistent in Lower-Risk MDS

June 3rd 2024, 1:00pm

Article

The safety profile of 200 milligrams and 300 milligrams of oral Ongureg were similar in patients with lower- to intermediate-risk MDS.

Enhertu Boosts PFS in Pretreated, HR-Positive, HER2-Low and -Ultralow Breast Cancer

June 2nd 2024, 7:00pm

Article

Enhertu lengthened the time to progression in patients with HR-positive, HER2-low or -ultralow metastatic breast cancer.

Chemo, Targeted Drugs Extremely Efficacious in HER2-Positive Breast Cancer

June 2nd 2024, 5:00pm

Video

Presurgical paclitaxel, Herceptin and Perjeta showed “incredible efficacy” in treatment of HER2-positive breast cancer.

Perioperative Chemo Shows Longer Survival in Esophageal Cancer

June 2nd 2024, 12:08pm

Article

Perioperative chemotherapy with chemotherapy led to improved survival outcomes versus neoadjuvant chemoradiation in resectable esophageal cancer.

Blenrep Combo Lengthens Time to Progression in Relapsed, Refractory Myeloma

June 2nd 2024, 12:02pm

Article

Blenrep, Pomalyst and dexamethasone improved progression-free survival compared to Velcade, Pomalyst and dexamethasone in patients with relapsed/refractory myeloma.

Neoadjuvant Opdivo Plus Yervoy Provides ‘Excellent Responses’ in Stage 3 Melanoma

June 2nd 2024, 12:00pm

Article

Opdivo plus Yervoy in the neoadjuvant setting reduced the risk for recurrence, progression or death, potentially offering patients with stage 3 melanoma a new standard of care.

Tagrisso Could Become Standard of Care for Some With EGFR+ NSCLC

June 2nd 2024, 12:00pm

Article

Tagrisso following chemoradiotherapy improved progression-free survival compared with placebo in stage 3 EGFR-mutated non–small cell lung cancer.